

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058028 A2

(51) International Patent Classification⁷: **A01K 67/02**

(21) International Application Number:
PCT/US2004/041721

(22) International Filing Date:
13 December 2004 (13.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/530,043 16 December 2003 (16.12.2003) US

(71) Applicants (*for all designated States except US*): **GENEN-TECH, INC.** [—/US]; MS 49, 1 DNA Way, South San Francisco, California 94080-4990 (US). **LEXICON GENETICS INCORPORATED** [—/US]; 8800 Technology Forest Place, The Woodlands, Texas 77381 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ANDERSON, Stephen** [US/US]; 30 N. Timber Top Drive, The Woodlands, Texas 77380 (US). **BRENNAN, Jane** [GB/US]; 700 Steiner Street #702, San Francisco, California 94117 (US). **DESAUVAGE, Frederic** [BE/US]; 187 Shooting Star Isle, Foster City, California 94404 (US). **DING, Zhiyong** [CN/US]; 3011 Spring Ranch Lane, Spring, Texas 77388 (US). **EDWARDS, Joel** [US/US]; 62 North Goldenvine Circle, The Woodlands, Texas 77382 (US). **FIKES, Nelda** [US/US]; 2400 Spring Rain #621, Spring, Texas 77379 (US). **HUANG, Wenhui** [CN/US]; 10 Shellbark Place, The Woodlands, Texas 77382 (US). **OUYANG, Wenjun** [CN/US]; 1057 Galley Lane, Foster City, California 94404 (US). **RANGEL, Carolina** [US/US]; 810 East 24th Street, Houston, Texas 77009 (US). **SANGHA, Mamta** [CN/US]; 21750 SW 103rd Court, Tualatin, Oregon 97062 (US). **SHI, Zheng-Zheng** [CN/US]; 53 Silver Crescent Court,

The Woodlands, Texas 77382 (US). **SPARKS, Mary Jean** [US/US]; 7218 Black Forest Drive, Magnolia, Texas 77354 (US). **TRACKEY, Joseph** [US/US]; 2301 South Millbend Drive #2414, The Woodlands, Texas 77380 (US). **VETTER, Melissa** [US/US]; 9110 Huckinston Court, Spring, Texas 77379 (US). **WANG, Ching-Yun** [CN/US]; 3 White Wing Court, The Woodlands, Texas 77382 (US). **WOODINGS, Jessica** [US/US]; 6 West Shaker Court, The Woodlands, Texas 77380 (US).

(74) Agents: **BARNES, Elizabeth** et al.; MS49 1 DNA Way, South San Francisco, California 94080-4990 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO

(57) Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO224, PRO9783, PRO1108, PRO34000, PRO240, PRO943, hu A33, PRO230, PRO178, PRO1199, PRO4333, PRO1336, PRO19598, PRO1083, hu TRPM2 or PRO1801 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.



WO 2005/058028 A2